70204-54-5

Upstream product

• 609-65-4 o-chlorobenzoyl chloride 
• 150-13-0 4-amino-benzoic acid 
• 118-91-2 ortho-chlorobenzoic acid 
• 94-09-7 p-aminoethylbenzoate 
• 75121-10-7 2-chloro-4'-ethoxycarbonylbenzanilide 

Downstream Products

• 1200404-09-6 2-chloro-N-(4-(((2-hydroxy-1-phenylpropyl)amino)carbonyl)phenyl)benzamide 
• 1200404-10-9 2-chloro-N-(4-(((2-oxo-1-phenylpropyl)amino)carbonyl)phenyl)benzamide 
• 1200404-33-6 2-chloro-N-(4-(5-phenyloxazol-2-yl)phenyl)benzamide 
• 1200404-12-1 2-chloro-N-(4-(5-methyl-4-phenyloxazol-2-yl)phenyl)benzamide 
• 1029765-77-2 C₂₂H₁₅ClN₂O₂ 
• 1200404-32-5 2-chloro-N-(4-(((2-hydroxy-2-phenylethyl)amino)carbonyl)phenyl)-benzamide 
• 1258550-48-9 2-chloro-N-(4-(3-nitro-4-(2-(phenylthio)ethylamino)phenylsulfonylcarbamoyl)phenyl)benzamide 

Relevant academic research and scientific papers

ROR GAMMA AGONISTS AS ENHANCERS OF PROTECTIVE IMMUNITY

The T cell specific RORgamma isoform RORgammat has been shown to be the key lineage-defining transcription factor to initiate the differentiation program of TH17 and TC17 cells, cells that have demonstrated anti-tumor efficacy, RORga

Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: Characteristics of broad-spectrum protein binding and its effects on anti-tumor activity

On the basis of the comparison of the structure of the Bim BH3: Bcl-x L complex and that of the ABT-737: Bcl-xL complex, a series of class A compounds were designed. These compounds had the basic skeleton of ABT-737 and the h2 residues of Bim BH3. These residues had shown themselves to be relevant to Bim BH3's broad-spectrum binding properties in saturation mutagenesis assays. Unlike ABT-737, which is a selective inhibitor of anti-apoptotic members of the Bcl-2 protein family, the class A compounds showed broad-spectrum binding activity to target proteins similar to those of Bim BH3 peptide. Then class B compounds were synthesized by modifying the structure of the most effective class A compound, A-4. Most of these class B compounds showed better binding affinity to the target proteins than the class A compounds had. They also showed themselves more effective than ABT-737 at inhibiting growth in multiple tumor cell lines known to express Bcl-x L, Bcl-2, and Mcl-1 proteins at high levels. Compounds B-11 and B-12 had the strongest anti-tumor activity of any compounds we produced. This study suggests that it is feasible to design small-molecule inhibitors based on the structure of Bim BH3, which shows broad-spectrum binding to Bcl-xL, Bcl-2, and Mcl-1 proteins. Our results also suggest that the broad-spectrum properties of small-molecule inhibitors binding to target proteins play a critical role in inhibiting the growth of many tumor cells. Finally, our study provides a series of lead compounds that merit further research into anti-cancer therapeutics.

OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

The present invention relates generally to compounds represented in Formula (I), pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer.

Synthesis of 4-substituted aminobenzoate quaternary salts as potent antispasmodic agents

N-(Diethylaminoethyl)-4-substituted aminobenzoate quaternary salts, N-(diethylaminoethyl)-4-substituted aminobenzamide quaternary salts, 4-substitued acylaminobenzamide quaternary salts, and 4-substituted acylaminosalicylamide derivatives were prepared and tested for antispasmodic activity. Preliminary pharmacological tests on isolated guinea pig ileum revealed that the new compounds possess nonspecific inhibitory action on smooth muscles.